Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.35 |
| ▸ | CDK2 | P24941 | 9/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264572 | 0.79 | ALDH1A1 (0.36) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1518098 | 0.73 | PDE10A (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL170250 | 0.72 | NPSR1 (0.36) | NPSR1 | |
| SCHEMBL10580470 | 0.72 | BACE1 (0.51) | KDM4EKMT2A | |
| SCHEMBL2561267 | 0.72 | PTPN1 (0.37) | LMNA | |
| SCHEMBL10579911 | 0.71 | AURKA (0.33) | — | |
| SCHEMBL3823196 | 0.69 | DPYD (0.42) | — | |
| SCHEMBL668116 | 0.69 | CYP3A4 (0.51) | ALDH1A1RAB9AKDM4EGAACYP1A2 | |
| SCHEMBL278550 | 0.69 | ALDH1A1 (0.41) | CA12CA1CA2CA9CA14 | |
| SCHEMBL9276901 | 0.69 | CA12 (0.39) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092389-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | AGILENT TECHNOLOGIES, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-4400584-A2 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | Agilent Technologies, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20230416733-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | AGILENT TECHNOLOGIES, INC. | 2023-12-28 | — | — | US | disclosed |
| CN-107250148-B | Guide RNAs with chemical modifications | 安捷伦科技有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20210079389-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | AGILENT TECHNOLOGIES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10900034-B2 | Guide RNA with chemical modifications | AGILENT TECHNOLOGIES, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10337001-B2 | Guide RNA with chemical modifications | AGILENT TECHNOLOGIES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180051281-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | AGILENT TECHNOLOGIES, INC. | 2018-02-22 | — | — | US | disclosed |
| EP-3227447-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | Agilent Technologies, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160289675-A1 | Guide RNA with chemical modifications | AGILENT TECHNOLOGIES, INC. | 2016-10-06 | — | — | US | disclosed |
| WO-2016089433-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | AGILENT TECHNOLOGIES, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079389-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | METTL16, ZFR, NSUN3 | CA12 3384/4885CA1 4633/4885CA2 4530/4885 |
| US-20230416733-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | METTL16, ZFR, NSUN3 | CA12 3384/4885CA1 4633/4885CA2 4530/4885 |
| US-20250092389-A1 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | METTL16, ZFR, NSUN3 | CA12 3384/4885CA1 4633/4885CA2 4530/4885 |
| US-10337001-B2 | Guide RNA with chemical modifications | METTL16, ZFR, NSUN3 | CA12 3384/4885CA1 4633/4885CA2 4530/4885 |
| US-10900034-B2 | Guide RNA with chemical modifications | METTL16, ZFR, NSUN3 | CA12 3384/4885CA1 4633/4885CA2 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.